- How different is the once-weekly teriparatide from the daily one or the same?
-
Takeuchia
- KMID: 2463602
- Osteoporos Sarcopenia.
- 2019 Jun;5(2):27-28.
- doi: 10.1016/j.afos.2019.06.004
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Diabetes and bone
-
Hygum K, Starup-Linde J, Langdahl B
- KMID: 2463603
- Osteoporos Sarcopenia.
- 2019 Jun;5(2):29-37.
- doi: 10.1016/j.afos.2019.05.001
Bone disease is a serious complication to diabetes. Patients with type 1 diabetes (T1D) and type 2 diabetes (T2D) suffer from an increased risk of fracture, most notably at the... -
- CITED
-
- Close
- SHARE
-
- Close
- Impact of patient background factors on the treatment efficacy of once-weekly teriparatide
-
Omura F
- KMID: 2463606
- Osteoporos Sarcopenia.
- 2019 Jun;5(2):51-56.
- doi: 10.1016/j.afos.2019.04.001
OBJECTIVES: The impact of patient background factors on changes in bone mineral density (BMD) and bone metabolic markers after treatment with once-weekly teriparatide (W-TPTD) has not been fully elucidated. To... -
- CITED
-
- Close
- SHARE
-
- Close
- The incidence of hip fracture and mortality rate after hip fracture in Korea: A nationwide population-based cohort study
-
Hong S, Han K
- KMID: 2463604
- Osteoporos Sarcopenia.
- 2019 Jun;5(2):38-43.
- doi: 10.1016/j.afos.2019.06.003
OBJECTIVES: Osteoporotic hip fractures are associated with high mortality in the older population. Few population studies have reported the long-term trends of incidence and mortality rate of hip fracture among... -
- CITED
-
- Close
- SHARE
-
- Close
- Additive effects of eldecalcitol in poorly responding long-term bisphosphonate treatment for osteoporosis
-
Kamimura M, Ikegami S, Mukaiyama , Koiwai H, Nakamura Y, Taguchi A, Kato H
- KMID: 2463607
- Osteoporos Sarcopenia.
- 2019 Jun;5(2):57-61.
- doi: 10.1016/j.afos.2019.06.001
OBJECTIVES: We examined whether eldecalcitol (ELD) provided additive bone mineral density (BMD) and bone turnover marker gains in patients undergoing long-term bisphosphonate (BP) usage, especially in osteoporotic individuals exhibiting a... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety and efficacy in actual clinical practice of once-weekly subcutaneous teriparatide for osteoporosis patients with a high fracture risk
-
Ifuku E, Yoshimura , Uzawa T, Hokonohara T
- KMID: 2463605
- Osteoporos Sarcopenia.
- 2019 Jun;5(2):44-50.
- doi: 10.1016/j.afos.2019.06.002
OBJECTIVES: To reassess the safety and efficacy of once-weekly teriparatide 56.5 mg in osteoporosis patients with a high fracture risk. METHODS: This postmarketing observational study was conducted at 72 weeks according... -
- CITED
-
- Close
- SHARE
-
- Close
